WASHINGTON, Nov 18 (Reuters) - A U.S. Food and Drug Administration advisory panel on Thursday:
* Said MELA Sciences' Melafind skin cancer system is safe
as proposed
* Said MELA Sciences' Melafind is shown to be effective
* Benefits of MELA Sciences' Melafind do outweigh its risks
* Votes 8-7 in favor of risk-benefit profile of MELA sciences'
Melafind for approval; one panelist abstains
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Said MELA Sciences' Melafind skin cancer system is safe
as proposed
* Said MELA Sciences' Melafind is shown to be effective
* Benefits of MELA Sciences' Melafind do outweigh its risks
* Votes 8-7 in favor of risk-benefit profile of MELA sciences'
Melafind for approval; one panelist abstains
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.